Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLL1 | O43897 | 3/20 | 0.82 |
| ▸ | TLL2 | Q9Y6L7 | 3/20 | 0.82 |
| ▸ | BMP1 | P13497 | 11/20 | 0.63 |
| ▸ | MMP12 | P39900 | 4/20 | 0.63 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20587305 | 1.00 | TLL1 (0.82) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL20587113 | 0.95 | TLL1 (0.90) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL20587112 | 0.95 | TLL1 (0.90) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL20587110 | 0.95 | TLL1 (0.90) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL16898152 | 0.95 | TLL1 (0.83) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL18241306 | 0.95 | TLL1 (0.83) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL16898150 | 0.95 | TLL1 (0.83) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL18375555 | 0.95 | TLL1 (0.78) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL18375590 | 0.94 | TLL1 (0.79) | TLL1TLL2BMP1MMP12SUCNR1 | |
| SCHEMBL20587162 | 0.94 | TLL1 (0.79) | TLL1TLL2BMP1MMP12SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-12-20 | — | — | US | disclosed |
| WO-2017006296-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | BMP1, BMP2, BMPR1A | TLL1 8/4885TLL2 10/4885BMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.